Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease

被引：0
|
作者：
Gkiouras, Konstantinos [1 ]
Grammatikopoulou, Maria G. [1 ,2 ]
Simopoulou, Theodora [1 ]
Daniil, Zoe [3 ]
Bogdanos, Dimitrios P. [1 ]
机构：
[1] Univ Thessaly, Dept Rheumatol & Clin Immunol, Fac Med, Sch Hlth Sci, Larisa, Greece
[2] Int Hellen Univ, Dept Nutr Sci & Dietet, Fac Hlth Sci, Alexander Campus, Thessaloniki, Greece
[3] Univ Thessaly, Dept Resp, Med Dept, Fac Med, Larisa, Greece
来源：
CLINICAL RHEUMATOLOGY | 2021年 / 40卷 / 08期
关键词：
METAANALYSES;
D O I：
10.1007/s10067-021-05845-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3379 / 3380
页数：2
相关论文
共 50 条
  • [41] Mycophenolate mofetil for scleroderma-related interstitial lung disease
    Zaheen, Ahmad
    Stanbrook, Matthew B.
    Anand, Anju
    LANCET RESPIRATORY MEDICINE, 2016, 4 (11): : E53 - E53
  • [42] Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease
    Assassi, Shervin
    Volkmann, Elizabeth R.
    Zheng, W. Jim
    Wang, Xuan
    Wilhalme, Holly
    Lyons, Marka A.
    Roth, Michael D.
    Tashkin, Donald P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 854 - 860
  • [43] \ Journal Club: Efficacy of Tocilizumab in Early Systemic Sclerosis-Related Interstitial Lung Disease
    Tiwari, Vivekanand
    Rigby, William F. C.
    ACR OPEN RHEUMATOLOGY, 2022, 4 (02) : 119 - 122
  • [44] The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease
    Bonella, Francesco
    Caramaschi, Paola
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (07) : 1034 - 1036
  • [45] Mycophenolate Mofetil Improves Exercise Tolerance in Systemic Sclerosis Patients with Interstitial Lung Disease: A Pilot Study
    Vaiarello, Valentina
    Schiavetto, Stefano
    Foti, Federica
    Gigante, Antonietta
    Iannazzo, Francesco
    Paone, Gregorino
    Palange, Paolo
    Rosato, Edoardo
    RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 1037 - 1044
  • [46] Mycophenolate Mofetil Improves Exercise Tolerance in Systemic Sclerosis Patients with Interstitial Lung Disease: A Pilot Study
    Valentina Vaiarello
    Stefano Schiavetto
    Federica Foti
    Antonietta Gigante
    Francesco Iannazzo
    Gregorino Paone
    Paolo Palange
    Edoardo Rosato
    Rheumatology and Therapy, 2020, 7 : 1037 - 1044
  • [47] Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (11) : 2045 - 2056
  • [48] Predicting Mortality in Systemic Sclerosis-Related Interstitial Lung Disease in Two Independent Cohorts
    Tashkin, D. P.
    Volkmann, E.
    Sim, M.
    Roth, M.
    Clements, P.
    Furst, D. E.
    Elashoff, R.
    Keyes-Elstein, L.
    Pinckney, A.
    Goldlmuntz, E.
    Sullivan, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [49] THERAPEUTIC STRATEGY COMBINING INTRAVENOUS CYCLOPHOSPHAMIDE FOLLOWED BY ORAL MYCOPHENOLATE MOFETIL TO TREAT SEVERE OR WORSENING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS
    Duchange, Al
    Mouthon, L.
    Berezne, A.
    Morell-Dubois, S.
    Hatron, P. Y.
    Guillevin, L.
    Hachulla, E.
    Launay, D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S165 - S165
  • [50] TREATMENT WITH CYCLOPHOSPHAMIDE FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE DOES NOT IMPROVE SURVIVAL AFTER 12 YEARS OF FOLLOW UP
    Volkmann, E. R.
    Sim, M.
    Tashkin, D. P.
    Khanna, D.
    Clements, P. J.
    Roth, M.
    Furst, D.
    Pickney, A.
    Goldmuntz, E.
    Keyes-Elstein, L.
    Elashoff, R.
    Sullivan, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 104 - 104
12345